Recent Updates
Recently added Catalysts

XmAb20717

Phase 2

Biliary Tract Cancer | Small molecule | Oncology |Xencor, Inc.|Last Updated: Sep 15, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment27
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05297903XmAb20717 in Advanced Biliary Tract CancersPHASE2 ACTIVE NOT_RECRUITING 27 — — Apr 11, 2022Dec 2, 2026Sep 15, 20251 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Objective Response Rate (ORR)
From therapy initiation, assessed at each restaging scan, for up to 24 months

Proportion of participants with the best response being complete response (CR) or partial response (PR)

Secondary Endpoints
Progression-free survival
From therapy initiation until progression or death, whichever comes first, for up to 60 months
Overall survival
From therapy initiation until death, for up to 60 months
Objective Response Rate (ORR) in patients that received prior immunotherapy
From therapy initiation, assessed at each restaging scan, for up to 24 months
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
XmAb20717EXPERIMENTALStudy participants will receive the recommended phase II dose (10mg/kg) of XmAb20717 by intravenous infusion on days 1 and 15 of a 28-day cycle for up to 2 years.
Interventions
NameTypeDescription
XmAb20717DRUG10mg/kg IV
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged \> 18 years of age 4. Patient must have advanced biliary tract cancers (BTC) including intrahep...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT05297903primaryCompletionDate: changed
LOWMay 24, 2026NCT05297903studyFirstPostDate: changed